Sol-gel Technologies vs Zhengye Biotechnology Holding
Sol-gel Technologies is the larger business, with $19.4m of revenue in fiscal 2025 against $16.2m for Zhengye Biotechnology Holding (1.2 times as much). Sol-gel Technologies grew faster (68.0% against -37.5%). Sol-gel Technologies kept more of each dollar of sales as profit: a net margin of -31.6% against -60.0%. Sol-gel Technologies carries less debt relative to equity (0.0% against 29.9%).
| Latest fiscal year | Sol-gel TechnologiesSLGL, 2025 | Zhengye Biotechnology HoldingZYBT, 2025 |
|---|---|---|
| Revenue | $19.4m | $16.2m |
| Revenue growth | 68.0% | -37.5% |
| Net income | −$6.1m | −$9.7m |
| Operating margin | -38.9% | -60.6% |
| Net margin | -31.6% | -60.0% |
| Return on equity | -23.7% | -26.0% |
| Free cash flow | $275,000 | $1.7m |
| Cash | $11.0m | $7.2m |
| Total debt | $0 | $10.7m |
| Debt to equity | 0.0% | 29.9% |
| Dividend per share | — | — |
| Dividend yield | — | 3.5% |
| Share buybacks | — | — |
| Employees | — | — |
| Market value | $184m | $61.6m |
| Price vs our value range | — | Above our value range |
| Moat score | — | — |
| Insider trades, 12 months | 49 buys, 0 sales | 0 buys, 0 sales |